Drug failures account for a substantial proportion of R&D costs and result from a variety of factors, many associated with drug safety and drug efficacy. When drugs fail because of safety concerns, a tremendous amount of resource expenditures are lost forever.
A multinational pharmaceutical and biologics company with operations in over 100 countries approached EPAM to develop a system that reduces manual effort in R&D, provides effective analysis of ongoing clinical trial information, and introduces best practices in defining the format and content of clinical trial reports. Read the full case study to learn how EPAM solved the issues.